Congenital Cytomegalovirus Infection in Malaysia: A Scoping Review, Clinical Insights and Future Directions
Main Article Content
Abstract
Congenital cytomegalovirus (cCMV) infection is the most common congenital infection worldwide, greatly contributing to neonatal morbidity and long-term neurological and audiological complications. Despite its clinical burden, cCMV remains underdiagnosed in Malaysia due to the absence of routine screening programmes and limited awareness among healthcare professionals. This review presents an overview of the epidemiology, clinical manifestations, diagnostic approaches, and management strategies of cCMV in Malaysia, highlighting gaps in current practices and potential future approaches. The seroprevalence of cytomegalovirus (CMV) among pregnant women in Malaysia is high, with reported maternal seropositivity rates between 74% and 84%. However, cCMV incidence remains poorly defined due to the lack of systematic screening. Clinical features range from asymptomatic infection to severe neurodevelopmental impairments, sensorineural hearing loss, and visual deficits. Current diagnostic methods rely on polymerase chain reaction (PCR)-based detection of CMV DNA from urine, saliva, or blood within the first three weeks of life. However, access to molecular testing is limited. Treatment with antiviral agents such as valganciclovir can improve neurodevelopmental outcomes, particularly in symptomatic infants, but remains underutilised due to cost and availability constraints. Emerging research on rapid antigen-based diagnostics and maternal antiviral prophylaxis offers opportunities for improving early detection and intervention. Future strategies should focus on increasing awareness among healthcare providers, implementing targeted or universal newborn screening, and promoting research on cost-effective diagnostic and treatment modalities. Strengthening national policies and integrating cCMV management into existing maternal and child health programmes is vital to mitigate its long-term impact.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Zuhair M, Smit GS, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019:29(5):e2034. https://doi.org/10.1002/rmv.2034
Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759–773. https://doi.org/10.1038/s41579-021-00582-z
Buca D, Di Mascio D, Rizzo G, et al. Outcome of fetuses with congenital cytomegalovirus infection and normal ultrasound at diagnosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2021;57(4):551–559. https://doi.org/10.1002/uog.23143
Goderis J, De Leenheer E, Smets K, et al. Hearing loss and congenital CMV infection: a systematic review. Pediatrics. 2014:134(5);972–982. https://doi.org/10.1542/peds.2014-1173
Plotkin SA, Wang D, Oualim A, Diamond DJ, Kotton CN, Mossman S, et al. The status of vaccine development against the human cytomegalovirus. J Infect Dis. 2020;221(Suppl 1):S113–S122. https://doi.org/10.1093/infdis/jiz447
Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86–102. https://doi.org/10.1128/CMR.00062-12
Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17(6):e177–e188. https://doi.org/10.1016/S1473-3099(17)30143-3
Davis NL, King CC, Kourtis AP. Cytomegalovirus infection in pregnancy. Birth Defects Res. 2017;109(5):336–346. https://doi.org/10.1002/bdra.23601
Faizal M, Nur Fazlin Akmal NF, Ramlah K, Salmuna Z. Cytokines expression in pregnant women with primary and non-primary cytomegalovirus (CMV) infection. Malays J Med Health Sci. 2022;18(3):103–111.
Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol. 2020;223(6):870–883.e11. https://doi.org/10.1016/j.ajog.2020.05.038
Pass RF, Fowler KB, Boppana SB, Britt WJ, Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol. 2006;35(2):216–220. https://doi.org/10.1016/j.jcv.2005.09.015
Ssentongo P, Hehnly C, Birungi P, Roach MA, Spady J, Fronterre C, et al. Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(8):e2120736. https://doi.org/10.1001/jamanetworkopen.2021.20736
Mussi-Pinhata MM, Yamamoto AY. Natural history of congenital cytomegalovirus infection in highly seropositive populations. J Infect Dis. 2020;221(Suppl 1):S15–S22. https://doi.org/10.1093/infdis/jiz443
Saraswathy TS, Az-Ulhusna A, Asshikin RN, Suriani S, Zainah S. Seroprevalence of cytomegalovirus infection in pregnant women and associated role in obstetric complications: a preliminary study. Southeast Asian J Trop Med Public Health. 2011;42(2):320–322.
Hamid N, Ismail N, Hashim A, Mohamad S, Salmuna Z. The prevalence of cytomegalovirus (CMV) infection among infants and correlation between CMV PCR with clinical outcomes in a tertiary teaching hospital in Malaysia. Sains Malaysiana. 2022;51(1):239–247. https://doi.org/10.17576/jsm-2022-5101-19
Tan DS, Cheah W, Sukumaran KD. The “TORCHES” (congenital diseases) programme in women of child-bearing age. Singapore Med J. 1976;17(4):212–215.
Tan DS, Stern H. A serological study of cytomegalovirus and herpes simplex virus infections in Peninsular Malaysia. Bull World Health Organ. 1981;59(6):909–912.
Balasubramaniam V, Sinniah M, Tan DS, Redzwan G, Lo’man SG. The role of cytomegalovirus (CMV) infection in congenital diseases in Malaysia. Med J Malaysia. 1994;49(2):113–116.
Nagy A, Endreffy E, Streitman K, Pintér S, Pusztai R. Incidence and outcome of congenital cytomegalovirus infection in selected groups of preterm and full-term neonates under intensive care. In Vivo. 2004;18(6):819–823.
Pitlick MM, Orr K, Momany AM, McDonald EL, Murray JC, Ryckman KK. Determining the prevalence of cytomegalovirus infection in a cohort of preterm infants. J Neonatal Perinatal Med. 2015;8(2):137–141. https://doi.org/10.3233/NPM-15814057
Turner KM, Lee HC, Boppana SB, Carlo WA, Randolph DA. Incidence and impact of CMV infection in very low birth weight infants. Pediatrics. 2014;133(3):e609–e615. https://doi.org/10.1542/peds.2013-2217
Yamamoto AY, Mussi-Pinhata MM, Cristina P, Pinto G, Moraes Figueiredo LT, Jorge SM. Congenital cytomegalovirus infection in preterm and full-term newborn infants from a population with a high seroprevalence rate. Pediatr Infect Dis J. 2001;20(2):188–192. https://doi.org/10.1097/00006454-200102000-00014
Pass RF, Fowler KB, Boppana SB, Britt WJ, Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol. 2006;35(2):216–220. https://doi.org/10.1016/j.jcv.2005.09.015
Payne H, Barnabas S.Congenital cytomegalovirus in Sub-Saharan Africa—a narrative review with practice recommendations. Front Public Health. 2024;12:1359663. https://doi.org/10.3389/fpubh.2024.1359663
Luck SE, Wieringa JW, Blázquez-Gamero D, Henneke P, Schuster K, Butler K, et al. Congenital Cytomegalovirus: A European expert consensus statement on diagnosis and management. Pediatr Infect Dis J. 2017;36(12):1205–1213. https://doi.org/10.1097/INF.0000000000001763
Alarcón A, de Vries LS, Parodi A, van Wezel-Meijler G, van der Knaap MS, Barkovich AJ. Neuroimaging in infants with congenital cytomegalovirus infection and its correlation with outcome: emphasis on white matter abnormalities. Arch Dis Child Fetal Neonatal Ed. 2024;109(2):F151–F158. https://doi.org/10.1136/archdischild-2023-325790
Vande Walle C, Keymeulen A, Schiettecatte E, Acke F, Dhooge I, Smets K, et al. Brain MRI findings in newborns with congenital cytomegalovirus infection: results from a large cohort study. Eur Radiol. 2021;31(11):8001–8010. https://doi.org/10.1007/s00330-021-07776-2
Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol. 2000;11(5):283–290. https://doi.org/10.1055/s-0042-1748054
Thorpe RK, Smith RJH. Future directions for screening and treatment in congenital hearing loss. Precis Clin Med. 2020;3(3):175–186. https://doi.org/10.1093/pcmedi/pbaa025
Fowler KB. Congenital cytomegalovirus infection: audiologic outcome. Clin Infect Dis. 2013;57(Suppl 4):S182–S184. https://doi.org/10.1093/cid/cit609
Ghekiere S, Allegaert K, Cossey V, Van Ranst M, Cassiman C, Casteels I. Ophthalmological findings in congenital cytomegalovirus infection: when to screen, when to treat? J Pediatr Ophthalmol Strabismus. 2012;49(5):274–282. https://doi.org/10.3928/01913913-20120710-03
Modrzejewska M, Połubiński P, Zdanowska O. Ophthalmic complications, diagnosis, and treatment of congenital human cytomegalovirus infection. J Clin Med. 2024;13(12):3379. https://doi.org/10.3390/jcm13123379
Boscarino G, Romano R, Tegoni F, Iotti C, Perrone S, Esposito S, et al. Congenital cytomegalovirus severity definitions and treatment decisions around the world: a systematic scoping review of the literature. J Clin Med. 2024;13(19):5997. https://doi.org/10.3390/jcm13195997
Pesch MH, Lauer CS, Weinberg JB. Neurodevelopmental outcomes of children with congenital cytomegalovirus: a systematic scoping review. Pediatr Res. 2024;95(2):418–435. https://doi.org/10.1038/s41390-023-02639-6
Khalil A, Heath PT, Jones CE, Soe A, Ville YG, Royal College of Obstetricians and Gynaecologists. Congenital cytomegalovirus infection: update on screening, diagnosis and treatment. BJOG. 2024;132(2):e42–e52. https://doi.org/10.1111/1471-0528.17966
Enders M, Daiminger A, Exler S, Enders G. Amniocentesis for prenatal diagnosis of cytomegalovirus infection: challenging the 21 weeks’ threshold. Prenat Diagn. 2017;37(9):940–942. https://doi.org/10.1002/pd.5107
Leruez-Ville M, Chatzakis C, Lilleri D, Rawlinson W, Kimberlin D, Boppana S, et al. Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI). Lancet Reg Health Eur. 2024;40:100892. https://doi.org/10.1016/j.lanepe.2024.100892
Prince HE, Lapé-Nixon M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy. Clin Vaccine Immunol. 2014;21(10):1377–1384. https://doi.org/10.1128/CVI.00487-14
Alifieraki S, Payne H, Hathaway C, Tan RWY, Lyall H. Delays in diagnosis and treatment initiation for congenital cytomegalovirus infection – why we need universal screening. Front Pediatr. 2022;10:988039. https://doi.org/10.3389/fped.2022.988039
Roberts SL, Kendall GS, Edwards S, Pandya P, Peebles D, Nastouli E, et al. Screening policies for cytomegalovirus in pregnancy in the era of antivirals. Lancet. 2022;400(10351):489–490. https://doi.org/10.1016/S0140-6736(22)01299-5
Grosse SD, Ross DS, Dollard SC. Newborn screening for congenital CMV: Evidence and implications. Pediatrics. 2022;139(2):e20213122.
Dollard SC, Dreon M, Hernandez-Alvarado N, Amin MM, Wong P, Lanzieri TM, et al. Sensitivity of dried blood spot testing for detection of congenital cytomegalovirus infection. JAMA Pediatr. 2021;175(3):e205441. https://doi.org/10.1001/jamapediatrics.2020.5441
Iijima S. Pitfalls in the serological evaluation of maternal cytomegalovirus infection as a potential cause of fetal and neonatal involvements: a narrative literature review. J Clin Med. 2022;11(17):5006. https://doi.org/10.3390/jcm11175006
Elmi AH, Irekeola AA, Abdullah MA, Mohamed Z. Detection of congenital toxoplasmosis and cytomegalovirus infections using paired sample serodiagnosis from suspected cases at a tertiary teaching hospital in Malaysia. Malays J Med Sci. 2024;31(4):101–110. https://doi.org/10.21315/mjms2024.31.4.8
Bilavsky E, Watad S, Levy I, Linder N, Pardo J, Ben-Zvi H, et al. Positive IgM in congenital CMV infection. Clin Pediatr (Phila). 2017;56(4):371–375. https://doi.org/10.1177/0009922816684596
Keymeulen A, De Leenheer E, Casaer A, Van Hoecke H, Dhooge I, Smets K, et al. Cranial ultrasound and MRI: complementary or not in the diagnostic assessment of children with congenital CMV infection? Eur J Pediatr. 2022;181(3):911–920. https://doi.org/10.1007/s00431-021-04273-y
Kandarpa H, Reddy M, Gianneschi G, Fofah O. Isolated, severe cerebellar hypoplasia and microcephaly secondary to congenital cytomegalovirus infection in a late preterm neonate. BMJ Case Rep. 2025;18(1):e263666. https://doi.org/10.1136/bcr-2024-263666
Vande Walle C, Keymeulen A, Schiettecatte E, Acke F, Dhooge I, Smets K, et al. Brain MRI findings in newborns with congenital cytomegalovirus infection: results from a large cohort study. Eur Radiol. 2021;31(11):8001–8010. https://doi.org/10.1007/s00330-021-07776-2
Lawson G, Sheeka A, Gaur P, Alifieraki S, Basheer N, Jan W, et al. Polymicrogyria in infants with symptomatic congenital cytomegalovirus at birth is associated with epilepsy: a retrospective, descriptive cohort study. Dev Med Child Neurol. 2025;60(8):1026–1033. https://doi.org/10.1111/dmcn.16250
Kimberlin DW, Lin CY, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J Pediatr. 2003;143(1):16–25. https://doi.org/10.1016/S0022-3476(03)00192-6
Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933–943. https://doi.org/10.1056/NEJMoa1404599
Kimberlin DW, Aban I, Peri K, Nishikawa JK, Ahmed A, Sanchez PJ, et al. Oral valganciclovir initiated beyond 1 month of age as treatment of sensorineural hearing loss caused by congenital cytomegalovirus infection: a randomized clinical trial. J Pediatr. 2024;268:113934. https://doi.org/10.1016/j.jpeds.2024.113934
Salomè S, Gammella R, Coppola C, Esposito S, Buonsenso D, Perrone S, et al. Can viral load predict a symptomatic congenital CMV infection? A systematic review and meta-analysis. Eur J Pediatr. 2025;184(1):188. https://doi.org/10.1007/s00431-025-06015-w
Marsico C, Aban I, Kuo H, James SH, Sanchez PJ, Ahmed A, et al. Blood viral load in symptomatic congenital cytomegalovirus infection. J Infect Dis. 2019;219(9):1398–1406. https://doi.org/10.1093/infdis/jiy695
Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther. 1993;53(1):15–21. https://doi.org/10.1038/clpt.1993.4
Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197(6):836–845. https://doi.org/10.1086/528376
Abu Bakar A, Payne H, Tickner N, Muhd Helmi MA, Jacobs TG, Lyall H. Dosing, toxicity and drug concentrations for ganciclovir/valganciclovir in preterm and low birthweight infants treated for cytomegalovirus. Pediatr Infect Dis J. 2025;44(4):319–325. https://doi.org/10.1097/INF.0000000000004605
DailyMed. Current medication information for VALCYTE (valganciclovir hydrochloride) tablet, film coated VALCYTE (valganciclovir hydrochloride) powder, for solution. [Internet]. U.S. National Library of Medicine. [Retrieved 2025 Feb 19]. Available at: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078
Märtson AG, Edwina AE, Kim HY, Knoester M, Touw DJ, Sturkenboom MGG, et al. Therapeutic drug monitoring of ganciclovir: where are we? Ther Drug Monit. 2022;44(1):138–147. https://doi.org/10.1097/FTD.0000000000000925
Luck S, Lovering A, Griffiths P, Sharland M. Ganciclovir treatment in children: evidence of sub-therapeutic levels. Int J Antimicrob Agents. 2010;37(2):173–175. https://doi.org/10.1016/j.ijantimicag.2010.11.033
Mareri A, Lasorella S, Iapadre G, Maresca M, Tambucci R, Nigro G. Antiviral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects. J Matern Fetal Neonatal Med. 2016;29(10):1657–1664. https://doi.org/10.3109/14767058.2015.1058774
Zammarchi L, Tomasoni LR, Liuzzi G, De Martino M, Galli L, Gabutti G, et al. Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: a real-life multicenter Italian observational study. Am J Obstet Gynecol MFM. 2023;5(10):101101. https://doi.org/10.1016/j.ajogmf.2023.101101
Egloff C, Sibiude J, Vauloup-Fellous C, Benachi A, Picone O, Vivanti AJ, et al. New data on efficacy of valacyclovir in secondary prevention of maternal-fetal transmission of cytomegalovirus. Ultrasound Obstet Gynecol. 2023;61(1):59–66. https://doi.org/10.1002/uog.26039
D’Antonio F, Marinceu D, Prasad S, Khalil A. Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2023;61(4):436–444. https://doi.org/10.1002/uog.26136
Foulon I, De Brucker Y, Buyl R, Lichtert E, Verbruggen K, Piérard D, et al. Hearing loss with congenital cytomegalovirus infection. Pediatrics. 2019;144(2):e20183095. https://doi.org/10.1542/peds.2018-3095
Forli F, Capobianco S, Berrettini S, Bruschini L, Lorenzoni F, Fiori S, et al. Long-term outcomes of congenital cytomegalovirus infection in children early identified by extended hearing-targeted screening. Int J Pediatr Otorhinolaryngol. 2024;184:112070. https://doi.org/10.1016/j.ijporl.2024.112070
Fourgeaud J, Magny JF, Couderc S, Garcia P, Maillotte AM, Benard M, et al. Predictors of the outcome at 2 years in neonates with congenital cytomegalovirus infection. Pediatrics. 2024;153(4):e2023063531. https://doi.org/10.1542/peds.2023-063531
Kanji A, Khoza-Shangase K, Moroe N. Newborn hearing screening protocols and their outcomes: A systematic review. Int J Pediatr Otorhinolaryngol. 2018;115:104–109. https://doi.org/10.1016/j.ijporl.2018.09.026
Gravel J, Berg A, Bradley M, Cacace A, Roush P, Sabo D, et al. New York State Universal Newborn Hearing Screening Demonstration Project: effects of screening protocol on inpatient outcome measures. Ear Hear. 2000;21(2):131–140. https://doi.org/10.1097/00003446-200004000-00007
Wróblewska-Seniuk K, Dąbrowski P, Szyfter W, Mazela J. Universal newborn hearing screening: methods and results, obstacles, and benefits. Pediatr Res. 2017;81(3):415–422. https://doi.org/10.1038/pr.2016.250
Ganesan S, Anusha M, Ranganathan L. A preliminary study on two-technology neonatal hearing screening. J Indian Speech Lang Hear Assoc. 2023;37:9–13. https://doi.org/10.4103/jisha.jisha_6_23
Shim J, Kim H, Kwon Y, Chang J, Park E, Im G. Results of a 10-year hearing screening using automated auditory brainstem response in newborns: The two-step AABR method. Int J Pediatr Otorhinolaryngol. 2021;151:110947. https://doi.org/10.1016/j.ijporl.2021.110947
Lanzieri TM, Chung W, Flores M, Blum P, Caviness AC, Bialek SR, et al. Hearing loss in children with asymptomatic congenital cytomegalovirus infection. Pediatrics. 2017;139(3):e20162610. https://doi.org/10.1542/peds.2016-2610
Keymeulen A, De Leenheer E, Casaer A, Cossey V, Laroche S, Mahieu L, et al. Neurodevelopmental outcome in children with congenital cytomegalovirus infection: a prospective multicenter cohort study. Early Hum Dev. 2023;182:105777. https://doi.org/10.1016/j.earlhumdev.2023.105777
Pesch MH, Muldoon KM. Congenital Cytomegalovirus knowledge, practices, and beliefs among primary care physicians and newborn hospitalists. J Prim Care Community Health. 2022;13:21501319221106880. https://doi.org/10.1177/21501319221106880
Castillo K, Hawkins-Villarreal A, Valdés-Bango M, Guirado L, Scazzocchio E, Porta O, et al. Congenital cytomegalovirus awareness and knowledge among health professionals and pregnant women: an action towards prevention. Fetal Diagn Ther. 2022;49(5–6):265–272. https://doi.org/10.1159/000525528
Korver AMH, De Vries JJC, De Jong JW, Dekker FW, Vossen ACTM, Oudesluys-Murphy AM. Awareness of congenital cytomegalovirus among doctors in the Netherlands. J Clin Virol. 2009;46(Suppl 1):S11–S15.
Schleiss MR, Panther L, Basnet S, Workneh M, Diaz-Decaro J. Comparison of overall sensitivity and specificity across different newborn screening algorithms for congenital cytomegalovirus. Int J Neonatal Screen. 2023;9(2):33. https://doi.org/10.3390/ijns9020033
Lantos PM, Gantt S, Janko M, Dionne F, Permar SR, Fowler K. A geographically weighted cost-effectiveness analysis of newborn cytomegalovirus screening. Open Forum Infect Dis. 2024;11(6):ofae311. https://doi.org/10.1093/ofid/ofae311
Chung PK, Schornagel F, Oudesluys-Murphy AM, de Vries LS, Soede W, van Zwet E, Vossen A. Targeted screening for congenital cytomegalovirus infection: clinical, audiological and neuroimaging findings. Arch Dis Child Fetal Neonatal Ed. 2023;108(3):302–308. https://doi.org/10.1136/archdischild-2022-324699
Fowler KB, McCollister FP, Sabo DL, Shoup AG, Owen KE, Woodruff JL, et al. A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. Pediatrics. 2017;139(2):e20162128. https://doi.org/10.1542/peds.2016-2128
Gkentzi D, Blázquez-Gamero D, Buxmann H, Drysdale SB, Papaevangelou V, Lyall H. Congenital CMV monthly international virtual clinics: a cCMVnet European initiative. Pediatr Infect Dis J. 2024;43(1):e26–e27. https://doi.org/10.1097/INF.0000000000004133
Biolatti M, Dell’Oste V, De Andrea M, Landolfo S. The human cytomegalovirus tegument protein pp65 (pUL83): a key player in innate immune evasion. New Microbiol. 2018;41(2):87–94.
Schleiss MR, Diamond DJ. Exciting times for cytomegalovirus (CMV) vaccine development: navigating the pathways toward the goal of protecting infants against congenital CMV infection. Vaccines. 2020;8(3):526. https://doi.org/10.3390/vaccines8030526
Panther L, Basnet S, Fierro C, Brune D, Leggett R, Peterson J, et al. 2892. Safety and immunogenicity of mRNA-1647, an mRNA-based cytomegalovirus vaccine in healthy adults: results of a phase 2, randomized, observer-blind, placebo-controlled, dose-finding trial. Open Forum Infect Dis. 2023;10(Suppl 2):ofad500.2475. https://doi.org/10.1093/ofid/ofad500.2475